10/31/14 AMAG 33.01 Amag Pharmaceuticals $AMAG Hit a 52 week high of 35.40 Closing the day 10/31/14 at 33.01 -0.95 -2.80% With a day low of 32.82 and a total volume of 424,000.
AMAG Recent Posts: http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:30PM CDT
Following the earnings release, shares of Affymetrix Inc. (AFFX) climbed 2.3% to close at $8.30 in the last session.
BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMAG: 33.01 (-0.95), AFFX: 9.01 (+0.71)
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:57AM CDT
AMAG Pharmaceuticals (AMAG) reported third-quarter 2014 earnings of 6 cents per share as compared to a loss of 1 cent per share incurred in the year-ago quarter.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), AMAG: 33.01 (-0.95)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
ACPW: 1.84 (+0.02), ACMP: 62.29 (-0.64), AMAG: 33.01 (-0.95), AMED: 26.10 (+0.82), ACCO: 8.23 (+0.33)
BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 321.08 (+0.08), AMAG: 33.01 (-0.95), BIND: 8.05 (-0.89), DYAX: 12.37 (+0.08)
Claims Administrator Angeion Group Announces Settlement in Silverstrand Investments v. AMAG Pharmaceuticals, Inc. Litigation
PR Newswire - Fri Oct 31, 7:00AM CDT
Angeion Group today announced that a settlement has been reached in a class action lawsuit against AMAG Pharmaceuticals, Inc. titled Silverstrand Investments et al. v. AMAG Pharmaceuticals, Inc. et al., in the United States District Court , District of Massachusetts, C.A. No. 10-CV-10470-NMG.
AMAG: 33.01 (-0.95)
AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Thu Oct 30, 6:11AM CDT
20% Growth Results in Record U.S. Feraheme Sales
AMAG: 33.01 (-0.95)
Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 4:20PM CDT
Teva (TEVA) is scheduled to report third-quarter 2014 results before the opening bell on Oct 30.
TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), BMY: 58.19 (-0.79)
Will Expedia Inc.'s (EXPE) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:56PM CDT
Expedia Inc. (EXPE) is set to report the third-quarter 2014 results on Oct 30. Last quarter, the company posted a 38.2% positive surprise. Let's see how things are shaping up for this announcement.
AMSG: 54.01 (+0.96), EXPE: 84.97 (+4.24), AMAG: 33.01 (-0.95), THRM: 41.70 (+3.60)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)
Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:01PM CDT
We expect Cigna (CI) to give a positive surprise when it reports its earnings on Oct 30, given its Zacks Rank #3 and a positive Earnings ESP.
CI: 99.57 (+2.47), INFI: 13.62 (-0.19), AMAG: 33.01 (-0.95), CRL: 63.16 (+0.35)
Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 1:22PM CDT
Sarepta Therapeutics (SRPT) shares plunged 32.5% on news that the company will not be submitting its NDA for eteplirsen.
BIIB: 321.08 (+0.08), RNA: 11.79 (+1.06), SRPT: 16.17 (+0.44), AMAG: 33.01 (-0.95)
Uptrend Call Working As AMAG Pharmaceuticals Stock Rises 62.3% (AMAG)
Comtex SmarTrend(R) - Tue Oct 28, 9:09AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 62.31% as of today's recent price of $33.93.
AMAG: 33.01 (-0.95)
Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:49AM CDT
Sarepta has been witnessing a flat trend in its current earnings estimate and it share price has been falling for past few days
BIIB: 321.08 (+0.08), SRPT: 16.17 (+0.44), AMAG: 33.01 (-0.95), ARRY: 3.59 (-0.28)
Can Corning (GLW) Surprise Earnings Estimates This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 3:22PM CDT
Corning (GLW) is set to report third-quarter 2014 results on Oct 28. Last quarter, it posted in-line results. Let's see how things are shaping up for this announcement.
AMSG: 54.01 (+0.96), AMAG: 33.01 (-0.95), GLW: 20.43 (+0.36), THRM: 41.70 (+3.60)
Will Baidu (BIDU) Disappoint Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 1:10PM CDT
Baidu, Inc. (BIDU) is set to report the third-quarter 2014 results on Oct 29. Last quarter, the company posted a 31.5% positive surprise.
AMSG: 54.01 (+0.96), BIDU: 238.77 (+1.76), AMAG: 33.01 (-0.95), THRM: 41.70 (+3.60)
Allergan Beats on Earnings, Revenues; Valeant Raises Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:52AM CDT
Allergan (AGN) reported third-quarter 2014 earnings of $1.78 per share, above the Zacks Consensus Estimate of $1.76.
AGN: 190.06 (+0.62), BIIB: 321.08 (+0.08), VRX: 133.04 (+1.53), AMAG: 33.01 (-0.95)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BHE: 23.72 (+0.40), ARPI: 19.00 (+0.05), BANR: 43.22 (+0.46), AMAG: 33.01 (-0.95), EGHT: 7.86 (+0.04)
AMAG Pharmaceuticals, Inc. to Host Conference Call on October 30, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Mon Oct 27, 7:02AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter and nine months ended September 30, 2014 before the U.S. financial markets open on Thursday, October 30, 2014. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the company's third quarter financial results and provide an update on business and regulatory matters, including the pending acquisition of the maternal health business of Lumara Health Inc.
AMAG: 33.01 (-0.95)
AMAG Pharmaceuticals Has Returned 50.7% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Oct 20, 4:47PM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.90. In approximately 2 months, AMAG Pharmaceuticals has returned 50.68% as of today's recent price of $31.50.
AMAG: 33.01 (-0.95)
Should You Buy AMAG Pharmaceuticals (AMAG) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
AMAG Pharmaceuticals could beat earnings estimates this season backed by favorable earnings estimate revision activity
AMAG: 33.01 (-0.95)
AMAG Recent Posts: http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:30PM CDT
Following the earnings release, shares of Affymetrix Inc. (AFFX) climbed 2.3% to close at $8.30 in the last session.
BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMAG: 33.01 (-0.95), AFFX: 9.01 (+0.71)
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:57AM CDT
AMAG Pharmaceuticals (AMAG) reported third-quarter 2014 earnings of 6 cents per share as compared to a loss of 1 cent per share incurred in the year-ago quarter.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), AMAG: 33.01 (-0.95)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
ACPW: 1.84 (+0.02), ACMP: 62.29 (-0.64), AMAG: 33.01 (-0.95), AMED: 26.10 (+0.82), ACCO: 8.23 (+0.33)
BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 321.08 (+0.08), AMAG: 33.01 (-0.95), BIND: 8.05 (-0.89), DYAX: 12.37 (+0.08)
Claims Administrator Angeion Group Announces Settlement in Silverstrand Investments v. AMAG Pharmaceuticals, Inc. Litigation
PR Newswire - Fri Oct 31, 7:00AM CDT
Angeion Group today announced that a settlement has been reached in a class action lawsuit against AMAG Pharmaceuticals, Inc. titled Silverstrand Investments et al. v. AMAG Pharmaceuticals, Inc. et al., in the United States District Court , District of Massachusetts, C.A. No. 10-CV-10470-NMG.
AMAG: 33.01 (-0.95)
AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Thu Oct 30, 6:11AM CDT
20% Growth Results in Record U.S. Feraheme Sales
AMAG: 33.01 (-0.95)
Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 4:20PM CDT
Teva (TEVA) is scheduled to report third-quarter 2014 results before the opening bell on Oct 30.
TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), BMY: 58.19 (-0.79)
Will Expedia Inc.'s (EXPE) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:56PM CDT
Expedia Inc. (EXPE) is set to report the third-quarter 2014 results on Oct 30. Last quarter, the company posted a 38.2% positive surprise. Let's see how things are shaping up for this announcement.
AMSG: 54.01 (+0.96), EXPE: 84.97 (+4.24), AMAG: 33.01 (-0.95), THRM: 41.70 (+3.60)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)
Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:01PM CDT
We expect Cigna (CI) to give a positive surprise when it reports its earnings on Oct 30, given its Zacks Rank #3 and a positive Earnings ESP.
CI: 99.57 (+2.47), INFI: 13.62 (-0.19), AMAG: 33.01 (-0.95), CRL: 63.16 (+0.35)
Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 1:22PM CDT
Sarepta Therapeutics (SRPT) shares plunged 32.5% on news that the company will not be submitting its NDA for eteplirsen.
BIIB: 321.08 (+0.08), RNA: 11.79 (+1.06), SRPT: 16.17 (+0.44), AMAG: 33.01 (-0.95)
Uptrend Call Working As AMAG Pharmaceuticals Stock Rises 62.3% (AMAG)
Comtex SmarTrend(R) - Tue Oct 28, 9:09AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 62.31% as of today's recent price of $33.93.
AMAG: 33.01 (-0.95)
Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:49AM CDT
Sarepta has been witnessing a flat trend in its current earnings estimate and it share price has been falling for past few days
BIIB: 321.08 (+0.08), SRPT: 16.17 (+0.44), AMAG: 33.01 (-0.95), ARRY: 3.59 (-0.28)
Can Corning (GLW) Surprise Earnings Estimates This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 3:22PM CDT
Corning (GLW) is set to report third-quarter 2014 results on Oct 28. Last quarter, it posted in-line results. Let's see how things are shaping up for this announcement.
AMSG: 54.01 (+0.96), AMAG: 33.01 (-0.95), GLW: 20.43 (+0.36), THRM: 41.70 (+3.60)
Will Baidu (BIDU) Disappoint Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 1:10PM CDT
Baidu, Inc. (BIDU) is set to report the third-quarter 2014 results on Oct 29. Last quarter, the company posted a 31.5% positive surprise.
AMSG: 54.01 (+0.96), BIDU: 238.77 (+1.76), AMAG: 33.01 (-0.95), THRM: 41.70 (+3.60)
Allergan Beats on Earnings, Revenues; Valeant Raises Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:52AM CDT
Allergan (AGN) reported third-quarter 2014 earnings of $1.78 per share, above the Zacks Consensus Estimate of $1.76.
AGN: 190.06 (+0.62), BIIB: 321.08 (+0.08), VRX: 133.04 (+1.53), AMAG: 33.01 (-0.95)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BHE: 23.72 (+0.40), ARPI: 19.00 (+0.05), BANR: 43.22 (+0.46), AMAG: 33.01 (-0.95), EGHT: 7.86 (+0.04)
AMAG Pharmaceuticals, Inc. to Host Conference Call on October 30, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Mon Oct 27, 7:02AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter and nine months ended September 30, 2014 before the U.S. financial markets open on Thursday, October 30, 2014. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the company's third quarter financial results and provide an update on business and regulatory matters, including the pending acquisition of the maternal health business of Lumara Health Inc.
AMAG: 33.01 (-0.95)
AMAG Pharmaceuticals Has Returned 50.7% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Oct 20, 4:47PM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.90. In approximately 2 months, AMAG Pharmaceuticals has returned 50.68% as of today's recent price of $31.50.
AMAG: 33.01 (-0.95)
Should You Buy AMAG Pharmaceuticals (AMAG) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
AMAG Pharmaceuticals could beat earnings estimates this season backed by favorable earnings estimate revision activity
AMAG: 33.01 (-0.95)
